Praxis Precision Medicines, Inc.

NasdaqGS:PRAX Stock Report

Market Cap: US$7.2b

Praxis Precision Medicines Management

Management criteria checks 4/4

Praxis Precision Medicines' CEO is Marcio De'Souza, appointed in Apr 2020, has a tenure of 6.17 years. total yearly compensation is $8.71M, comprised of 7.6% salary and 92.4% bonuses, including company stock and options. directly owns 0.086% of the company’s shares, worth $6.14M. The average tenure of the management team and the board of directors is 5.1 years and 4.6 years respectively.

Key information

Marcio De'Souza

Chief executive officer

US$8.7m

Total compensation

CEO salary percentage7.57%
CEO tenure6.2yrs
CEO ownership0.09%
Management average tenure5.1yrs
Board average tenure4.6yrs

Recent management updates

Recent updates

Seeking Alpha • Jun 05

Praxis' Premium Price May Reflect Unrealistic Market Prospects In Essential Tremor

Summary Praxis Precision Medicines, Inc. is valued as a pure-play on ulixacaltamide’s commercial launch in essential tremor, with pipeline optionality limited. I maintain a cautious Hold rating, as PRAX trades above my fair value estimate of $223.73 versus a current share price of $265. Key risks include real-world persistence, payer step edits, and competition from cheap off-label generics, which could materially limit ulixacaltamide’s addressable market and duration. Pipeline assets outside ET, such as elsunersen and vormatrigine, offer little valuation support, especially after recent clinical setbacks and negative risk-adjusted NPV. Read the full article on Seeking Alpha
Analysis Article • Jul 18

We're Hopeful That Praxis Precision Medicines (NASDAQ:PRAX) Will Use Its Cash Wisely

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Seeking Alpha • Mar 04

Praxis: A High-Risk, High-Reward Epilepsy Play Post Ulixacaltamide (Rating Upgrade)

Summary Ulixacaltamide’s Phase 3 study was recommended to stop for futility, significantly lowering its chances of success in essential tremor. Investor focus shifts to the epilepsy pipeline, led by vormatrigine (focal epilepsy) and relutrigine (SCN2A/SCN8A-DEEs). Vormatrigine must differentiate from Xcopri and XEN1101 in a highly competitive focal epilepsy market. Relutrigine showed promising seizure reduction in rare pediatric epilepsies but needs confirmation in larger pivotal trials. Praxis has $400M+ cash, funding operations into 2028, with key epilepsy trial readouts expected in 2H 2025. Read the full article on Seeking Alpha
Seeking Alpha • Dec 26

Praxis Precision Medicines: Multiple Potential Drivers

Summary Praxis Precision Medicines, Inc., a promising clinical stage biopharma concern, has seen significant stock gains in the second half of 2024. Analyst firms are quite bullish on the stock, with eight firms recently issuing Buy ratings and price targets ranging from $114 to $305 per share. The company has several potential drivers with its late-stage pipeline candidates and possesses a decent balance sheet. While the stock should only be considered by aggressive investors given its recent rally, I have taken a small position in PRAX stock via covered call orders. An analysis around Praxis Precision Medicines follows in the paragraphs below. Read the full article on Seeking Alpha
Seeking Alpha • Oct 13

Praxis Precision Medicines: Great Price Movement, But Still Not Convinced

Summary Praxis Precision Medicines has shown impressive growth, but past trial failures and current risks warrant caution before investing. The lead candidate, Ulixacaltamide, is in a phase 3 trial for essential tremor, with results expected by the end of 2024. PRAX-628 shows promise for epilepsy, but the small patient cohort and competitive landscape raise concerns. Despite significant stock gains, I remain unconvinced and seek more data before making an investment decision. Read the full article on Seeking Alpha
Seeking Alpha • Mar 26

Praxis: 2nd Half 2024 ET Readout Could Lead To U.S. Regulatory Filing

Summary Praxis Precision Medicines, Inc. results from the phase 3 Essential3 program, using ulixacaltamide for the treatment of patients with essential tremor, expected in the 2nd half of 2024. Company believes that the essential tremor U.S. market opportunity could be $4 billion. Positive data achieved in phase 2 study, using PRAX-628 for focal epilepsy; Phase 2b study targeting this very same patient population to be initiated 2nd half of 2024. With cash on hand, plus underwritten public offering that brought in $161.7 million in cash, Praxis Precision Medicines believes it can fund its operations into 2026. Read the full article on Seeking Alpha

CEO Compensation Analysis

How has Marcio De'Souza's remuneration changed compared to Praxis Precision Medicines's earnings?
DateTotal CompensationSalaryCompany Earnings
Mar 31 2026n/an/a

-US$327m

Dec 31 2025US$9mUS$659k

-US$303m

Sep 30 2025n/an/a

-US$273m

Jun 30 2025n/an/a

-US$251m

Mar 31 2025n/an/a

-US$213m

Dec 31 2024US$13mUS$640k

-US$183m

Sep 30 2024n/an/a

-US$151m

Jun 30 2024n/an/a

-US$124m

Mar 31 2024n/an/a

-US$125m

Dec 31 2023US$2mUS$625k

-US$123m

Sep 30 2023n/an/a

-US$138m

Jun 30 2023n/an/a

-US$157m

Mar 31 2023n/an/a

-US$183m

Dec 31 2022US$6mUS$625k

-US$214m

Sep 30 2022n/an/a

-US$231m

Jun 30 2022n/an/a

-US$232m

Mar 31 2022n/an/a

-US$208m

Dec 31 2021US$11mUS$571k

-US$167m

Sep 30 2021n/an/a

-US$135m

Jun 30 2021n/an/a

-US$111m

Mar 31 2021n/an/a

-US$88m

Dec 31 2020US$12mUS$385k

-US$70m

Compensation vs Market: Marcio's total compensation ($USD8.71M) is about average for companies of similar size in the US market ($USD8.37M).

Compensation vs Earnings: Marcio's compensation has been consistent with company performance over the past year.

CEO

Marcio De'Souza (47 yo)

6.2yrs
Tenure
US$8,708,648
Compensation

Mr. Marcio Silva De'Souza M.B.A., has been President, Chief Executive Officer and Director of Praxis Precision Medicines, Inc. since April 2020. Mr. De'Souza joined the Praxis Precision Medicines, Inc. in...

Leadership Team

NamePositionTenureCompensationOwnership
Marcio De'Souza
President6.2yrsUS$8.71m0.086%
$ 6.1m
Timothy Kelly
CFO & Treasurer5.1yrsUS$3.20m0.033%
$ 2.3m
Alex Nemiroff
General Counsel & Secretary6yrsUS$2.84m0.024%
$ 1.7m
Steven Petrou
Co-Founder and President of Research & Developmentno datano datano data
Megan Sniecinski
Chief Operating Officerless than a yearno data0.024%
$ 1.7m
Karl Hansen
Chief Technical Operations Officer4.5yrsno datano data
Kelly McCue
Chief People Officer5.5yrsno data0.013%
$ 963.2k
Alyssa J. Wyant
Chief Regulatory & Quality Officer5.8yrsno datano data
Brian Spar
Chief of Staff4.3yrsno datano data
Orrin Devinsky
Head of Clinical Strategyless than a yearno datano data
5.1yrs
Average Tenure
49yo
Average Age

Experienced Management: PRAX's management team is seasoned and experienced (5.1 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Marcio De'Souza
President6.2yrsUS$8.71m0.086%
$ 6.1m
William Young
Independent Director9.5yrsUS$418.72k0.0068%
$ 488.4k
Dean Mitchell
Independent Chairman of the Board5.8yrsUS$445.22k0.062%
$ 4.4m
Gregory Norden
Independent Director7.3yrsUS$426.22k0.00067%
$ 48.1k
Merit Cudkowicz
Independent Director5.2yrsUS$416.72k0%
$ 0
Jill DeSimone
Independent Director4.1yrsUS$421.22k0.0035%
$ 248.9k
Jeffrey Chodakewitz
Independent Director5.2yrsUS$412.72k0%
$ 0
Anna Greka
Member of Scientific Advisory Board3.4yrsno datano data
Matthew Might
Chairman of the Scientific Advisory Board3.4yrsno datano data
Holger Lerche
Member of Scientific Advisory Board3.4yrsno datano data
Ivan Soltesz
Member of Scientific Advisory Board3.4yrsno datano data
Samuel Berkovic
Member of Scientific Advisory Board3.4yrsno datano data
4.6yrs
Average Tenure
69yo
Average Age

Experienced Board: PRAX's board of directors are considered experienced (4.6 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/06/17 01:55
End of Day Share Price 2026/06/17 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Praxis Precision Medicines, Inc. is covered by 27 analysts. 17 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Brian SkorneyBaird
Joel BeattyBaird
null nullBaird